cd20/cd22 targeted car t-cells
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 23, 2018 (NCT04283006)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- B-lymphocyte antigen CD20Immunity, passive
MS4A1 immunity, passive
- CD22Immunity, passive
CD22 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04283006 | Early Phase 1 (Phase 1) | May 23, 2018 | Yake Biotechnology Ltd., Zhejiang University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Yake Biotechnology Ltd. | Government | 1 | 0 | 1 | 2018 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2018 |
2 organizations
Page 1 / 1